Pierre Fabre and Lonza Enter Manufacturing Agreement
Lonza will produce drug product for Pierre Fabre’s monoclonal antibody W0180.
Lonza announced that it has entered into a manufacturing agreement with Pierre Fabre on June 15, 2022. Lonza will provide Pierre Fabre with drug product manufacturing services for clinical supply from its fill/finish facility in Stein, Switzerland.
According to a company press release, the collaboration is aimed at manufacturing W0180, a monoclonal antibody (mAb) that is currently being investigated as a single agent and in combination with pembrolizumab in various solid tumors. It targets the V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), a negative checkpoint regulator of T-cell response that is expressed in the tumor microenvironment. The mAb is currently in a Phase I clinical trial.
"The W0180 will be manufactured in Lonza's GS Xceed Expression CHO [Chinese hamster ovary] System, also successfully used for the IGF1R [insulinlike growth factor1 receptor] and cMet antibodies discovered by Pierre Fabre," said Jean-Luc Lowinksi, CEO, Pierre Fabre Medical Care.
Source: Pierre Fabre
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
